Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Weng, Meng Tzu ^a,b   Tung, Tzu Hsun ^c   Lee, Jih Hsiang ^d   Wei, Shu Chen ^e   Lin, Hang Li ^e   Huang, Yu Jung ^c   Wong, Jau Min ^e   Luo, Ji ^f   Sheu, Jin Chuan ^e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c Liver Disease Prevention and Treatment Research Foundation   (Taiwan)

^d National Clinical Trial Statistical Center   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; ATM PROTEIN; CELL CYCLE PROTEIN; CHECKPOINT KINASE 1; CHEK1 PROTEIN, HUMAN; CHEK1 PROTEIN, MOUSE; ERH PROTEIN, HUMAN; MESSENGER RNA; PROTEIN KINASE; TRANSCRIPTION FACTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHEMISTRY; DNA DAMAGE; DNA REPAIR; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HEP-G2 CELL LINE; HUMAN; LIVER; LIVER NEOPLASMS; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; RADIATION RESPONSE; RNA INTERFERENCE; ULTRAVIOLET RADIATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHECKPOINT KINASE 1; DNA DAMAGE; DNA REPAIR; DRUG SYNERGISM; HEP G2 CELLS; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN KINASES; RNA INTERFERENCE; RNA, MESSENGER; TRANSCRIPTION FACTORS; ULTRAVIOLET RAYS;

EID: 84928036717     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09357     Document Type: Article

References (48)

1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127, 2893-2917 (2010).
2. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet. 379, 1245-1255 (2012).
3. Llovet, J.M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359, 378-390 (2008).
4. Burroughs, A., Hochhauser, D. & Meyer, T. Systemic treatment and liver transplantation for hepatocellular carcinoma: Two ends of the therapeutic spectrum. Lancet Oncol. 5, 409-418 (2004).
5. Kan, Z. et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23, 1422-1433 (2013).
6. Totoki, Y. et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet. 43, 464-469 (2011).
7. Yang, S. F. et al. Involvement of DNA Damage Response Pathways in Hepatocellular Carcinoma. Biomed Res Int. 2014, 153867 (2014).
8. Yildiz, G. et al. Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis. PloS one. 8, e64016 (2013).
9. Guo, G. S. et al. DNA repair and synthetic lethality. Int J Oral Sci. 3, 176-179 (2011).
10. Wojcik, E., Murphy, A. M., Fares, H., Dang-Vu, K. & Tsubota, S. I. Enhancer of rudimentaryp1, e(r)p1, a highly conserved enhancer of the rudimentary gene. Genetics. 138, 1163-1170 (1994).
11. Weng, M. T. et al. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A. 109, E3659-3667 (2012).
12. Liu, Q. et al.Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14, 1448-1459 (2000).
13. Wang, X. et al. Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress. Mol Cell. 23, 331-341 (2006).
14. Wang, H. et al. CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBV-positive hepatocellular carcinoma cells. Biochem Biophys Res Commun. 422, 103-108 (2012).
15. Roessler, S. et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70, 10202-10212 (2010).
16. Zheng, S., Tansey, W. P., Hiebert, S. W. & Zhao, Z. Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma. BMC Med Genomics. 4, 62 (2011).
17. Olive, P. L., Banath, J. P.&Durand, R. E. Heterogeneity in radiation-inducedDNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res. 122, 86-94 (1990).
18. Guo, Z., Kumagai, A., Wang, S. X. & Dunphy, W. G. Requirement for Atr in phosphorylation of Chk1 and cell cycle regulation in response to DNA replication blocks and UV-damaged DNA in Xenopus egg extracts. Gene Dev. 14, 2745-2756 (2000).
19. Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPAssDNA complexes. Science 300, 1542-1548 (2003).
20. Zabludoff, S. D. et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 7, 2955-2966 (2008).
21. Hassepass, I., Voit, R. & Hoffmann, I. Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J. Biol Chem. 278, 29824-29829 (2003).
22. Parsels, L. A. et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res. 17, 3706-3715 (2011).
23. Higgs, M. R., Chouteau, P. & Lerat, H. ?Liver let die': Oxidative DNA damage and hepatotropic viruses. J Gen Virol 95, 991-1004 (2014).
24. Capovilla, A., Carmona, S. & Arbuthnot, P. Hepatitis B virus X-protein binds damagedDNAand sensitizes liver cells to ultraviolet irradiation. Biochem Biophys Res Commun. 232, 255-260 (1997).
25. Mathonnet, G., Lachance, S., Alaoui-Jamali, M. & Drobetsky, E. A. Expression of hepatitis B virus X oncoprotein inhibits transcription-coupled nucleotide excision repair in human cells. Mutat Res. 554, 305-318 (2004).
26. Becker, S. A., Lee, T. H., Butel, J. S. & Slagle, B. L. Hepatitis B virus X protein interferes with cellular DNA repair. J. Virol. 72, 266-272 (1998).
27. Duong, F. H. et al. Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53. Carcinogenesis. 35, 114-122 (2014).
28. Bittar, C., Shrivastava, S., Bhanja Chowdhury, J., Rahal, P. & Ray, R. B.Hepatitis C virus NS2 protein inhibits DNA damage pathway by sequestering p53 to the cytoplasm. PloS one 8, e62581 (2013).
29. Bhargava, A. et al.Occult hepatitis C virus elicits mitochondrial oxidative stress in lymphocytes and triggers PI3-kinase-mediatedDNAdamage response. Free Radic Biol Med. 51, 1806-1814 (2011).
30. Bhargava, A. et al. Occult hepatitis B virus infection with low viremia induces DNA damage, apoptosis and oxidative stress in peripheral blood lymphocytes. Virus Res. 153, 143-150 (2010).
31. Schwarz, K. B. et al. Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Dig Dis Sci. 46, 2173-2178 (2001).
32. Tanaka, S. et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol. 48, 1249-1258 (2013).
33. Shawki, S. M.,Meshaal, S. S., El Dash, A. S., Zayed, N. A.&Hanna, M. O. Increased DNA damage in hepatitis C virus-related hepatocellular carcinoma. DNA Cell Biol. 33, 884-890 (2014).
34. Fujita, N. et al. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J. Viral Hepat. 15, 498-507 (2008).
35. Hong, J. et al. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Invest. 122, 2165-2175 (2012).
36. Ho, C. C. et al. The relative contribution of CHK1 and CHK2 to Adriamycininduced checkpoint. Exp Cell Res. 304, 1-15 (2005).
37. Bunch, R. T. & Eastman, A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res. 2, 791-797 (1996).
38. Tse, A. N. et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res. 13, 591-602 (2007).
39. McNeely, S. et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell cycle. 9, 995-1004 (2010).
40. Landau, H. J. et al. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther. 11, 1781-1788 (2012).
41. Sausville, E. et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 73, 539-549 (2014).
42. Garrett, M. D. & Collins, I. Anticancer therapy with checkpoint inhibitors: What, where and when? Trends Pharmacol Sci. 32, 308-316 (2011).
43. Waters, D. J. et al. Noninvasive prediction of prostatic DNA damage by oxidative stress challenge of peripheral blood lymphocytes. Cancer Epidermiol Biomarkers Prev. 16, 1906-1910 (2007).
44. Duthie, S. J. &Collins, A. R. The influence of cell growth, detoxifying enzymes and DNA repair on hydrogen peroxide-mediated DNA damage (measured using the comet assay) in human cells. Free Radic Biol Med. 22, 717-724 (1997).
45. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22, 27-55 (1984).
46. Bandyopadhyay, A. et al. Doxorubicin in combination with a small TGFbeta inhibitor: A potential novel therapy for metastatic breast cancer in mouse models. PloS one. 5, e10365 (2010).
47. Venkatesha, V. A. et al. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia. 14, 519-525 (2012).
48. Wei, S. C., Tsao, P. N., Weng, M. T., Cao, Z. & Wong, J. M. Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. J. Biomed Sci. 20, 39 (2013).